Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02038647 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
NCT02038647 is a Phase 2 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 178 participants.
The verdict
NCT02038647, a Phase 2 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
Study Summary
This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study designed to is to determine if the combination treatment can improve progression free survival (defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occurs first) when compared with placebo + paclitaxel.
Interventions
- DRUG Placebo
- DRUG Paclitaxel
- DRUG Alisertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2014-05-12 |
| Est. Completion | 2017-07-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02038647
The ClinicalTrials.gov registry entry for NCT02038647 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02038647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02038647 about?
NCT02038647 is a clinical study titled "Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)". This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study designed to is to determine if the combination treatment can improve progression free survival (defined as the time from the date of randomization to the date of first documentation of disease progression or ...
What is the current status of trial NCT02038647?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2014-05-12. Estimated completion is 2017-07-10.
What interventions are being tested in trial NCT02038647?
The interventions under investigation include: Placebo (DRUG), Paclitaxel (DRUG), Alisertib (DRUG).
Who is sponsoring clinical trial NCT02038647?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.